Cardio3 BioSciences (C3BS) has increased its business development activities, building on its core expertise in cellular therapies and in cardiovascular diseases.

Since its inception, Cardio3 BioSciences has demonstrated its competency in cellular therapy, from R&D to manufacturing, to regulatory clinical trials; Cardio3 BioSciences is now engaged in C-Cure's Phase III regulatory pivotal trials process in Europe, U.S., and China. Cardio3 BioSciences has developed in parallel its technical expertise in medical devices, with the manufacturing of a proprietary cell delivery system, C-Cathez. Finally, the Company, with its deep understanding of cardiology, led to the close collaboration with a unique network of top- ranking cardiovascular institutions around the world. These accomplishments represent a solid platform for further growth.

This focused approach to business development around a technology pillar (cellular therapies) and a clinical application pillar (cardiovascular diseases), will lead to a number of unmet medical needs and market opportunities across different therapeutic approaches in cellular therapies and cardiovascular diseases. In cellular therapies, this could cover applications in immune modulation, regeneration or oncology. In cardiovascular diseases this could lead to multiple treatment modalities, such as devices or biologics.

Cardio3 BioSciences' business development strategy is intended to build a coherent, sustainable and highly profitable business entity building on the solid C-Cure foundations.

Dr Christian Homsy, CEO of Cardio3 BioSciences, said We intend to build a strong sustainable world leader in the areas identified in our business development strategy. C- Cure is the foundation of...

To continue reading